GENENTECH'S COVID-19 RESPONSE
Genentech takes the health and safety of our patients, customers, employees and local communities very seriously. See below for information on how we're actively responding to the global COVID-19 pandemic.
Information & Resources
Frequently Asked Questions
Read our responses to frequently asked questions regarding COVID-19 and Genentech.
Learn moreContact Information & Support Resources
View contact information and support resources for patients, medical professionals, and customers.
Learn morePatient Financial Support
We believe every person should get the Genentech medicine they need, and we offer programs to help make this happen.
Learn MoreNews & Editorials
Topline results from our Phase III trial on COVID-19 associated pneumonia.
Read the press release on the new IL-6 biomarker test from our parent company, Roche.
Read the press release on the new Anti-SARS-CoV-2 antibody test from our parent company, Roche.
Read more about how we are actively responding to the global COVID-19 pandemic.
Read the news about our EMPACTA trial of Actemra, focused on underserved and minority patients.
Learn more about our Phase III trial for hospitalized patients with severe COVID-19 pneumonia.
Read about our Phase III trial testing the combination of two investigational medicines for severe COVID-19 pneumonia.
Read the press release on the SARS-CoV-2 test from our parent company, Roche.
SARS-CoV-2 & Influenza A/B Test
Read the press release on the SARS-CoV-2 & Influenza A/B test from our parent company, Roche.
Learn more about our commitment to help address the impacts of COVID-19 in our communities and across the U.S.
Global Manufacturing Collaboration
Learn about how Genentech and Roche are joining forces with Rengeron in the fight against COVID-19.
If we all continue to work together, I believe science will ultimately prevail over this disease.